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Objective: Infliximab is an effective treatment for refractory or fistulizing Crohn's disease (CD). However, 
about 30% of patients do not respond to infliximab for unknown reasons. Identifying predictive factors of 
response is important for optimizing clinical management and for better understanding infliximab's mechanisms 
of action. The aim of this study was to assess whether demographic or clinical parameters influence short-term 
response to infliximab. 
Methods: The first 240 CD patients of the Belgian Infliximab Expanded Access Program were studied for 
response to infliximab treatment and assessed at 4 (refractory luminal CD) or 10 wk (fistulizing CD) after the 
first infusion. Detailed demographic and clinical information on age, sex, type of disease (fistulizing or 
refractory), Crohn's Disease Activity Index score, C-reactive protein (CRP), smoking habits, disease duration, 
localization of disease, concomitant medication, and previous surgery were obtained from all patients. Logistic 
regression and decision tree analysis were performed. 
Results: There were 73.5% responders and 26.5% nonresponders to treatment. Stepwise logistic regression 
identified age (OR = 0.971, 95% CI = 0.947-0.995, p = 0.018), isolated ileitis (OR = 0.359, 95% CI = 0.177-
0.728, p = 0.004), and previous surgery (OR = 0.429, 95% CI = 0.233-0.787, p = 0.006) as inversely correlated 
with response, whereas isolated colitis (OR = 1.905, 95% CI = 1.010-3.597, p = 0.046) and concomitant 
immunosuppressive treatment (OR = 2.670, 95% CI = 1.430-5.016, p = 0.0022) were positively correlated with 
response to infliximab. Surprisingly, smoking habits were not retained as predictors for response. Decision tree 
analysis provided a working algorithm based on age and immunosuppressive treatment that warrants further 
exploration. 
Conclusions: In this large cohort of infliximab-treated CD patients, young age, Crohn's colitis, and concomitant 




Without a definitive cure for Crohn's disease (CD), the current management (i.e., a combination treatment of 5-
aminosalicylates, corticosteroids, immunomodulating drugs, and antibiotics) aims at suppressing intestinal 
inflammation. The search for new drugs mainly focuses on the immune cascade and cytokine interactions, and a 
number of new immune modulating agents have been clinically investigated. In 1994, the efficacy of the murine-
human monoclonal chimeric antibody against tumor necrosis factor-α (TNF-α, infliximab, Remicade) in the 
treatment of severe refractory rheumatoid arthritis was reported (1); soon afterward, this therapy also proved to 
be effective in severe refractory CD (2). Meanwhile, three placebo-controlled, double blind, randomized trials in 
CD have been published that show overall response rates of 65% (3-5). Infliximab has proved to be a major 
breakthrough in the management of both refractory and fistulizing CD. Although long-term efficacy and safety 
results remain unknown, the short- and medium-term clinical efficacy are very good; the duration of response 
after a single infusion ranges between 6 wk to 24 months, with a median of 12 wk (6-8). When patients are 
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retreated with one infusion every 8 wk, sustained remission is observed in 50% of patients (5). Treatment with 
infliximab is also associated with significant healing of endoscopic lesions and disappearance of the mucosal 
inflammatory infiltrate at the histological level (9, 10). However, some concerns remain. The lack of efficacy in 
about one third of patients as well as the high cost of the repeated infusions support the need for the 
identification of patient subgroups who will clearly benefit from the drug. 
Response does not seem to be a matter of dosing (3), although selected patients may benefit from higher doses 
(11). Patients who do not respond to one infusion are unlikely to do so after another; however, the 
prognosticators that determine response or lack of response are still unknown. Targan et al. (3) could not identify 
any clinical parameters predictive of response to infliximab. In the study of Present et al. (4), concomitant use of 
azathioprine (AZA) seemed to encourage healing of fistulas. Also, in the retreatment study (5), a trend toward a 
positive influence of concomitant AZA treatment on infliximab response was seen, as 75% of patients taking 
AZA were still in remission 8 wk after the last infusion (at 44 wk), compared with 50% of patients who were not 
taking AZA. Besides clinical characteristics, demographic parameters have also been studied with respect to 
response prediction. However, published trials so far have not included smoking habits, one of the best known 
environmental risk factors influencing the clinical course of CD (3-8). 
In general, defining demographic and clinical parameters that could predict response would contribute to a better 
understanding of the pathogenesis of the disease. In addition, they may provide insight into the mechanisms of 
action of infliximab, and may also lead to improved cost-effectiveness. Therefore, in this study, we assessed 
whether demographic or clinical parameters could predict short-term response in a large cohort of infliximab-
treated CD patients. 
MATERIALS AND METHODS 
Patients 
The first 240 CD patients of the Belgian Infliximab Expanded Access Program (Schering-Plough NV/SA, Study 
number P01246-1) were included in this study. Demographic characteristics, clinical parameters, and outcome 
data were recorded. Of this cohort, 137 (57.1%) patients received infliximab for refractory luminal disease and 
103 (42.9%) for fistulizing disease. The demographic data and baseline clinical characteristics obtained are 
summarized in Table 1. Approval for the study was given by the Ethical Committees of the respective 
institutional boards where the study was ongoing, and all patients gave written informed consent before enrolling 
in the trial. 
Treatment 
Infliximab (Remicade; Centocor, Malvern, PA) was given as an i.ν. infusion of 5 mg/kg in all patients. Eligible 
patients had to belong to one of the following groups: 1) they had to have single or multiple enterocutaneous 
draining fistula(s) as a complication of CD resistant to conventional treatment for at least 3 months ("severe" 
fistula patients); 2) they had to have moderately to severely active CD of at least 6 months' duration, with colitis, 
ileitis, or ileocolitis confirmed by radiography or endoscopy, and refractory or dependent on oral corticosteroid 
therapy (>8 mg/day prednisone equivalent); or 3) they were refractory or intolerant to methotrexate (MTX), 
AZA, 6-mercaptopurine (6-MP), or cyclosporine (started at least 12 wk before enrollment in the trial). Patients 
defined as dependent on corticosteroids were patients who failed all attempts to wean steroids completely. 
According to the protocol of the Expanded Access Program, patients with refractory luminal disease received a 
single infusion at wk 0. For fistulizing disease, three consecutive infusions at weeks 0, 2, and 6 were 
administered. 
Evaluation of Efficacy 
Response was determined at 4 or 10 wk after first infusion for refractory luminal or fistulizing CD, respectively. 
According to the criteria used in the study by Targan et al. (3) for luminal disease, patients were scored as 
cpmplete responders (remission) or partial responders when the Crohn's Disease Activity Index score (12) was 
<150 or when a reduction of ≥70 points in the Crohn's Disease Activity Index score was obtained, respectively. 
For fistulizing disease, response was defined as complete in the case of complete cessation of draining of the 
fistula despite gentle finger compression, and as partial in the case of an at least 50% decrease of the number of 
draining fistulae from baseline at two consecutive visits, respectively (4). 
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Table 1. Demographic and Baseline Clinical Characteristics of the Study Population (N = 240) 
 Refractory CD (n = 137) Fistulizing CD (n = 103) All Patients (N = 240) 
Mean baseline CDAI (range) 294 (72-609) 200 (51-526) 261 (51-609) 
Mean baseline CRP (mg/L) 24.5 24.9 24.7 
Median age (yr) (IQR) 34 (28-44) 37 (30-46) 36 (28-4475) 
Female/male (%) 84/53 (61.3/38.7) 69/34 (67.0/33.0) 153/87 (63.8/36.2) 
Smoking (%) 68 (49.6) 39 (37.8) 107 (44.6) 
Mean disease duration (yr) 10.7 13.0 11.7 
Involved intestinal area    
Ileitis (%) 23 (16.8) 17 (16.5) 40 (16.7) 
Ileocolitis (%) 70(51.1) 35 (34.0) 105 (43.8) 
Colitis (%) 43 (31.4) 46 (44.7) 89 (37.1) 
Localization of fistulas    
Perianal  69  
Rectovaginal  23  
Enterocutaneous  19  
Into bladder  1  
Enterocolic  1  
Concomitant treatment    
Aminosalicylates (%) 59 (43.1) 47 (45.6) 106 (44.2) 
Steroids (%) 75 (54.7) 33 (32.0) 108 (45.0) 
6-MP/AZA/MTX (%) 76 (55.5) 64 (62.1) 140 (57.9) 
Oral contraceptives 31 (22.6) 21 (20.4) 52 (21.7) 
NSAIDs 8 (5.8) 5 (4.9) 13 (5.4) 
Previous abdominal surgery 51 (37.2) 31 (30.1) 82 (34.2) 
CDAI = Crohn's Disease Activity Index; NSAID = nonsteroidal anti-inflammatory drugs. 
 
Statistical Analysis 
Data were analyzed by means of a stepwise logistic regression and decision tree analysis (DTA), both 
implemented in SAS/STAT, release 8.01 (SAS Institute, Cary, NC). Whereas logistic regression enables the 
identification of independent variables associated with the defined target, decision tree analysis allows adding a 
weight to these variables. DTA (SAS Enterprise Miner) splits data into binary branches (CART option) 
according to the values of variables and continues splitting branches in an iterative process that leads to the target 
value. Each split depends on the value of only one variable x. Suppose that there are M variables: at each node, 
the tree algorithm searches through the variables one by one, beginning with xl up to xm. For each variable, the 
best split is found, and the M best single variable splits are compared to select the best of the best. DTA will 
reject variables that play no role in arriving at the target. SAS Enterprise Miner divides the data set randomly 
into a training data set (±70% of data) used for model fitting, and a validation data set (±30% of data) to assess 
the adequacy of the model. In this way, DTA generates a working algorithm that, in turn, can be applied to new 
data and be scored. In contrast with a regression model, DTA does not allow for deducing significant interactions 
between variables. The results reported in the next section were obtained with a significance level of α = 0.05; 
all reported p values are two-sided. 
RESULTS 
Six patients of the total cohort (2.5%) could not be evaluated for response because of confounding factors 
(psychiatric disorders, n = 2; short bowel syndrome, n = 1; acute surgery, n = 2; liver transplant and need for new 
concomitant immune suppressive treatment, n = 1) and were therefore excluded from further analysis. Of the 
remaining 234 patients evaluable for response, 172 of 234 (73.5%) were responders (of whom 110 of 234 
(47.0%) entered remission and 62 of 234 (26.5%) showed partial response), whereas 62 of 234 (26.5%) did not 
respond to infliximab. Response rates for fistulous and luminal disease were 74.3% and 72.9%, respectively. The 
following noteworthy adverse events were seen: seven patients experienced acute infusion reactions, two patients 
developed a lupus-like syndrome, three patients developed hematological problems (one autoimmune hemolytic 
anemia, one leukopenia, one pancytopenia), and three patients developed a malignancy (one prostate cancer, one 
cervical cancer, and one desmoid tumor). 
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Stepwise logistic regression identified the following variables: age (OR = 0.971, 95% CI = 0.947-0.995, p = 
0.018), presence of isolated ileitis (OR = 0.359, 95% CI = 0.177-0.728, p = 0.004), and previous surgery (OR = 
0.429, 95% CI = 0.233-0.787, p = 0.006) were inversely correlated with response, whereas isolated colitis (OR = 
1.905, 95% CI = 1.010-3.597, p = 0.046) and concomitant immunosuppressive treatment (OR = 2.670, 95% CI = 
1.430-5.016, p = 0.0022) were positively correlated with response to infliximab (Table 2). There were 140 
patients taking concomitant immunomodulating drugs, 127 AZA or 6-MP, and 13 MTX. Among the 13 patients 
taking MTX, nine of 13 were responders and four of 13 were nonresponders. However, no significant results 
were reached when this subgroup was analyzed separately, possibly because of the small number of patients. The 
significant influence of concomitant immunosuppressive medications on response is mainly due to AZA. 
Subanalysis with only those patients taking AZA/6-MP (leaving out those patients on MTX) was even more 
significant (OR = 2.773, 95% CI = 1.485-5.178, p = 0.0014). 
If outcome was defined on the basis of remission rather than response, comparable results were obtained: 
namely, colitis (p = 0.019) and immunosuppressive treatment (p = 0.001) were positively associated with 
remission. More advanced age (p = 0.061), ileitis (p = 0.008), and previous surgery (p = 0.001) were associated 
with poor response. 
 
Table 2. Comparison of Responders (Remission or Partial) Versus Nonresponders for the Demographic and 
Clinical Characteristics Studied (Logistic Regression—SAS/STAT) 
 Response (n = 172) Nonresponse (n = 62) OR (95% CI) p Value 
Mean baseline CDAI 254 268 0.99 (0.996-1.002) 0.48 
Mean baseline CRP (mg/L) 25.6 22.5 1.00 (0.988-1.020) 0.63 
Median age (yr) (IQR) 33 (27-41.25) 41.5 (32-49) 0.971 (0.947-0.995) 0.018 
Female/male (%) 108/64 (62.8/37.2) 40/22 (64.5/35.5) 0.993 (0.505-1.953) 0.98 
Smoking (%) 80 (46.5) 26 (41.9) 1.38 (0.674-2.809) 0.38 
Type of disease: fist/refractory 75/97 (43.6/56.4) 26/36 (41.9/58.1) 0.707 (0.319-1.568) 0.39 
Mean disease duration (yr) 10.8 13.1 1.006 (0.972-1.041) 0.74 
Involved intestinal area     
Ileitis (%) 22 (12.8) 18 (25.0) 0.359 (0.177-0.728) 0.004 
Ileocolitis (%) 78 (45.3) 27 (43.5) 1.071 (0.595-1.927) 0.82 
Colitis (%) 72 (41.9) 17 (23.6) 1.905 (1.010-3.597) 0.046 
Concomitant treatment     
Aminosalicylates (%) 81 (47.0) 23 (37.1) 1.721 (0.880-3.363) 0.11 
Steroids (%) 77 (44.8) 30 (48.4) 0.866 (0.443-1.691) 0.67 
6-MP/AZA/MTX (%) 110 (63.9) 25 (40.3) 2.670 (1.430-5.016) 0.0022 
Oral contraceptives 40 (23.3) 12 (19.4) 0.859 (0.432-1.700) 0.66 
NSAIDs 8 (4.6) 5 (8.1) 0.800 (0.237-2.700) 0.72 
Previous abdominal surgery 51 (29.6) 31 (50.0) 0.429 (0.233-0.787) 0.006 
Abbreviations as in Table 1. 
 
The regression model allowed us to look for interactions between certain variables. There was no interaction 
between age and colonic involvement, or between age and concomitant immunosuppressive drugs. However, a 
positive interaction of concomitant immunosuppressive drugs on colonic involvement was seen: of 191 patients 
with Crohn's colitis who were evaluable for response, 95 of 147 (64.6%) responders were taking AZA, compared 
to only 18 of 44 (40.9%) of nonresponders (OR = 0.394, 95% CI = 0.197-0.789, p = 0.009). Inversely, the 
presence of colitis did not have any additional beneficial effect on concomitant immunosuppressive intake 
toward treatment response. 
Smoking habits did not influence response to infliximab; 80 of 106 (75.5%) smokers showed response, which 
was not significantly different from the response seen in nonsmokers (89 of 128, 69.5%) (OR = 1.376; 95% CI = 
0.674-2.809, p = 0.38). Furthermore, in smokers, the same ratio for response/nonresponse was observed, 
regardless of concomitant immunosuppressive intake. This implied that there was no interaction between 
smoking and immunomodulator therapy, as suggested in other studies (13). 
Subsequently, patients with fistulizing and luminal disease were analyzed separately. For refractory luminal 
disease only, the following variables were significantly related with response: age (OR = 0.961, 95% CI = 0.929-
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0.995, p = 0.024), ileitis (OR = 0.325, 95% CI = 0.128-0.824, p = 0.018), and concomitant immunosuppressive 
treatment (OR = 2.917, 95% CI = 1.292-6.587, p = 0.010). In the subgroup of fistulizing disease, young age and 
previous surgery were the only significant parameters (OR = 0.961, 95% CI = 0.926-0.998, p = 0.037 and OR = 
0.345, 95% CI = 0.128-0.930, p = 0.035, respectively). The concomitant intake of immunosuppressive treatment 
was borderline significant (OR = 2.48, 95% CI = 0.997-6.17, p = 0.0508). 
The same input variables were used in the decision tree analysis (Fig. 1). For the whole data set, age was the first 
splitting variable: for a cut-off of age <39.5 yr, 82% of the training and 84% of the validating data set would be 
correctly classified toward infliximab response. The purity of the node age <39.5 yr could not be improved 
further by the program and, hence, the splitting stopped. For the node age >39.5 yr, only 55.9% and 64.5% 
would correctly be classified toward response for the training and validation data set, respectively. However, 
AZA was defined as the second splitting variable in this node, and prediction of response improved to 70.8% and 
71.4%, respectively, with concom itant AZA therapy. No other variables, including disease localization or 
previous surgery, could be identified in this decision tree that could further improve our model. Given the fact 
that DTA is created for large data sets of information, no subanalysis of fistulizing and luminal CD was 
performed. 
 
Figure 1. Decision tree analysis (using SAS enterprise Miner; see text) on the total study population (n = 240). 
Absolute numbers as well as percentage of response (R) and nonresponse (NR) for the training data set (left 
column) and validation data set (right column) are given. Age was selected as the first splitting variable to 





Treatment refractoriness is a serious problem for a chronic disorder such as CD. Because the pathogenesis of CD 
is still unknown, there is no cure for the disease, and current treatment focuses on suppressing the intestinal 
inflammation. Therapy refractoriness is not a new problem in the clinical management of inflammatory bowel 
disease (IBD). From the very first introduction of corticosteroids, it was shown that 20% of patients do not 
respond, and 36% of responders develop steroid dependency (14). AZA/6-MP is effective in up to 50% of 
patients who are dependent on or refractory to corticosteroids (15); however, 25% of patients still do not 
respond. MTX is an alternative for patients who do not respond or who are intolerant to AZA/6-MP (16). 
Recently, the introduction of monoclonal antibodies against TNF-α was a major achievement in the treatment of 
diseases such as IBD and rheumatoid arthritis. Approximately 170,000 patients worldwide have since been 
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treated (two thirds of patients for rheumatoid arthritis and one third of patients for IBD) worldwide and results 
are promising, with overall response rates around 65%. However, again we are confronted with a group of 
nonresponding patients. Therefore, it is of great importance to find clinical, biochemical, or immunological 
parameters to predict treatment failure. Indeed, if treatment fails, patients remain symptomatic and are at 
increased risk for complications, hospital admissions, and even surgery. 
To our knowledge, the present study is the largest to date on demographic and clinical parameters influencing 
short-term response to initial infliximab infusions. We observed 74% responders to treatment and 26% 
nonresponders. These data are similar to findings of three large published trials (3-5) as well as subsequently 
published cohort-studies (6-8). In our study, response to infiiximab in the total cohort was associated with a 
young age, colitis, and—probably most importantly—the concomitant intake of immunomodulating drugs. In 
only those patients with refractory luminal CD, young age and concomitant use of immunomodulators were 
associated with response, whereas isolated ileitis was associated with poor response. For fistulizing CD, young 
age also favored response, whereas previous abdominal surgery was associated with poor response. Probably 
colonic disease did not hold up in these stratified analyses because of widened confidence intervals resulting 
from decreased sample size. We did not observe a change in the point estimates of the OR when comparing OR 
of the total regression model, as compared to the model stratified according to disease type. 
None of the randomized trials or the three recent retrospective studies showed any significant association 
between, for example, AZA/6-MP treatment and initial response to infliximab, probably because of a lack of 
statistical power. Although in the retreatment study it was suggested that concomitant immunosuppressive 
treatment may favor response, no significance was reached (5). It must be noted that in the present study we 
looked at the response to initial infiiximab infusions; this is different from maintenance of remission with 
repeated infiiximab treatment, in which case AZA/6-MP treatment may be beneficial by preventing attenuation 
of response to repeated infliximab infusions. 
The study by Cohen et al. also found that concurrent therapy with 6-MP or AZA (but not MTX) resulted in a 
higher response and remission rates to initial infliximab infusion when compared to patients not receiving any of 
these additional immunomodulators; but, again, no significance was reached (6). Although the results of that 
study should be treated with caution (given that this was a retrospective study rather than a randomized trial), the 
efficacy data in rheumatoid arthritis clearly demonstrate the synergistic effect of concomitant 
immunosuppressive treatment on infliximab response (17). 
Decision tree analysis selected age, with a cut-off of 39.5 yr, as the best variable to predict response. Patients 
under this age are more likely to respond. In the older group of patients, in contrast, the response was lower but 
could substantially be improved by concomitant use of AZA. Whether use of infliximab should be advocated in 
these elderly patients who are not taking immunosuppressive drugs remains to be determined. A first step is to 
confirm our results in independent patient cohorts to see whether treatment guidelines can be optimized further 
in the future. It is not clear why younger patients would have a better response. One hypothesis is that the better 
outcome in younger patients could be related to a shorter duration of their disease. However, our results could 
not prove this. It is well known that there is a functional decline in both the adaptive and innate immune systems 
with increasing age (18). Several hypotheses try to explain this so-called immune senescence: reduction in the 
synthesis and release of hormones or neurotransmitters; alterations in the number, density, and affinity of 
receptors; diminished receptor responsiveness; and/or alterations in biochemical events distal to the 
hormone/receptor site. Maybe the question why older patients respond less well should be focused in this 
direction. 
Although logistic regression identified disease localization and previous abdominal surgery as other independent 
variables associated with response, in the decision tree model, these variables were less important than age and 
concomitant AZA treatment, and could not further improve the predictive model. 
Interestingly, smoking habits were not retained as predictive factors from our analysis. It has been shown that 
smoking is associated with a more severe course of CD and with an increased risk for surgery. The same authors 
found that immunosuppressive therapy neutralizes the influence of smoking on surgical rates (13). However, the 
possibility that the negative results for smoking in our study were caused by the neutralizing effect of 
concomitant immunosuppressive treatment could not be demonstrated. 
Because CD results from an interaction among environmental, genetic, and immunological factors, anti-TNF 
treatment may tackle only part of the etiopathogenesis of CD. Other factors are still present that will also define 
clinical outcome. Biological availability of infliximab in the serum, among other factors, seems to be an 
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important determinant of response. It is mandatory to continue the search for clinical parameters that can identify 
those patients who are more likely to benefit from current or new treatments. In this respect, studies on genetic 
polymorphisms, serological markers, and cytokine profiles could add more insight into the problem and could 
improve our understanding in the mechanisms of action of drugs. More importantly, however, the insights 
derived from such studies would enable practitioners to better serve our patients with CD by offering them a 
more efficacious, individually tailored therapeutic management. 
In conclusion, in this large cohort of infliximab-treated patients with CD, young age, concomitant 
immunosuppressive treatment, and isolated colitis were independent variables of response to infliximab, whereas 
previous abdominal surgery and isolated ileitis were associated with poor response. These results may have 
important clinical implications for future management of CD with infliximab. Decision tree analysis further 
provided a working algorithm to be prospectively tested. 
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